Advertisement

European Journal of Dermatology

, Volume 28, Issue 3, pp 320–325 | Cite as

Coexistence of Kaposi’s sarcoma and psoriasis: is there a hidden relationship?

  • Lucia Brambilla
  • Giovanni Genovese
  • Athanasia Tourlaki
  • Silvia Della Bella
Clinical Report

Abstract

Background

The relationship between Kaposi’s sarcoma (KS) and psoriasis is still controversial.

Objectives

To analyse the association between KS and psoriasis, address the hypothesis of a reciprocal influence between the two conditions relative to clinical presentation and evolution, and consider the best therapeutic approach to be used for the treatment of psoriasis in KS patients in order to avoid the typical induction or worsening of KS during immunosuppression.

Materials & Methods

We retrospectively reviewed clinical records of 37 patients with KS and psoriasis. Fisher’s exact test was performed in order to compare epidemiological and clinical data between subsets of patients.

Results

The prevalence of psoriasis in our KS population (n = 1407) was 2.6%. There were no statistically significant differences in terms of stage or rate of progression between KS patients with and without psoriasis, except for a higher frequency of patients with KS Stage IIB among patients with KS and psoriasis (p = 0.001).

Conclusions

Patients with psoriasis have a risk of KS comparable to that of the general population. Psoriasis and KS do not appear to influence each other. For the treatment of psoriasis in KS patients, one should take into account the KS-inducing potential of certain anti-psoriatic drugs.

Key words

Kaposi’s sarcoma psoriasis psoriatic arthritis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Supplementary material

40699_2018_3288_MOESM1_ESM.pdf (920 kb)
Coexistence of Kaposi’s sarcoma and psoriasis: is there a hidden relationship?

References

  1. 1.
    Reich K. The concept of psoriasis as a systemic inflammation:implications for disease management. J Eur Acad Dermatol Venereol 2012; 26: 3–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Hanahan D, Weinberg RA. Hallmarks of cancer:the next generation. Cell 2011; 144: 646–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis:a systematic review and meta–analysis of epidemiological studies. J Eur Acad Dermatol Venereol 2013; 27: 36–46.CrossRefPubMedGoogle Scholar
  4. 4.
    Ganem D. KSHV and the pathogenesis of Kaposi sarcoma:listening to human biology and medicine. J Clin Invest 2010; 120: 939–49.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tebbe B, Mayer–da–Silva A, Garbe C, von Keyserlingk HJ, Orfanos CE. Genetically determined coincidence of Kaposi sarcoma and psoriasis in an HIV–negative patient after prednisolone treatment. Spontaneous regression 8 months after discontinuing therapy. Int J Dermatol 1991; 30: 114–20.PubMedGoogle Scholar
  6. 6.
    Selvi E, De Stefano R, Manganelli S, Marcolongo R. Kaposi’s sarcoma in psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 389.CrossRefGoogle Scholar
  7. 7.
    Sorce M, Bongiorno MR. Simultaneous diagnosis of Kaposi’s sarcoma, psoriasis, vitiligo and monoclonal gammopathy of undetermined significance in an immunocompetent patient. J Dermatol 2013; 40: 479–80.CrossRefPubMedGoogle Scholar
  8. 8.
    Fargnoli MC, Peris K, Frascione P, et al. Psoriasis. Kaposi’s sarcoma and Hodgkin’s disease in a patient with Down’s syndrome. Dermatology 2004; 209: 158–9.Google Scholar
  9. 9.
    Bielan B. What’s your assessment? Psoriasis with Kaposi sarcoma. Dermatol Nurs 2005; 17: 30–1.PubMedGoogle Scholar
  10. 10.
    Ursini F, Naty S, Mazzei V, Spagnolo F, Grembiale RD. Kaposi’s sarcoma in a psoriatic arthritis patient treated with infliximab. Int Immunopharmacol 2010; 10: 827–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Dervis E, Demirkesen C. Kaposi’s sarcoma in a patient with psoriasis vulgaris. Acta Dermatovenerol Alp Pannonica Adriat 2010; 19: 31–4.PubMedGoogle Scholar
  12. 12.
    Häring N, Strohal R, Kemmler N. Kaposi sarcoma in a psoriasis patient. J Dtsch Dermatol Ges 2012; 10: 65–6.PubMedGoogle Scholar
  13. 13.
    Philipp S, Kokolakis G, Hund M, et al. Immunological changes in psoriasis patients under long–term treatment with fumaric acid esters:risk of Kaposi sarcoma occurrence? Eur J Dermatol 2013; 23: 339–43.PubMedGoogle Scholar
  14. 14.
    Verdelli A, Bonciani D, Bonciolini V, Caproni M. Is tocilizumab safe in Kaposi sarcoma? A complex association among rheumatoid arthritis, psoriasis, and Kaposi sarcoma. Clin Drug Investig 2014; 34: 437–8.PubMedGoogle Scholar
  15. 15.
    Tyros G, Potouridou I, Tsaraklis A, et al. A generalized Kaposi’s sarcoma after chronic and extensive topical corticosteroid use. Eur J Dermatol 2014; 24: 111–2.PubMedGoogle Scholar
  16. 16.
    Florek AG, Eilers D, Armstrong AW. A case of Kaposi sarcoma in an immunocompetent, heterosexual Irish man:a discussion of etiology and viral transmission. Dermatol Online J 2015; 21: 10.Google Scholar
  17. 17.
    Yoo J, Jo M, Kim MS, Choi KH, Park HJ, Jue MS. Hidden pictures of Kaposi’s sarcoma in psoriatic lesions:a diagnostic challenge. Ann Dermatol 2016; 28: 749–52.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Taylor WJ, Gladman DD, Helliwell PS, et al. Classification criteria for psoriatic arthritis:results from the CASPAR study group. Arthritis Rheum 2006; 54: 2665–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi sarcoma:a useful tool for therapeutic choices. Eur J Dermatol 2003; 13: 83–6.PubMedGoogle Scholar
  20. 20.
    Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K. Kaposi sarcoma and Merkel cell carcinoma after autoimmune disease. Int J Cancer 2012; 131:e326–8.CrossRefGoogle Scholar
  21. 21.
    Lowes MA, Suárez–Fari˜nas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014; 32: 227–55.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ensoli B, Stürzl M, Monini P. Reactivation and role of HHV–8 in Kaposi’s sarcoma initiation. Adv Cancer Res 2001; 81: 161–200.CrossRefPubMedGoogle Scholar
  23. 23.
    Saggini A, Chimenti S, Chiricozzi A. IL–6 as a druggable target in psoriasis:focus on pustular variants. J Immunol Res 2014; 2014: 964069.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Miles SA, Testa M, Huang J, Wade M, Carden J, Scadden DT. Lack of tumor activity and intolerance of interleukin–4 in patients with advanced HIV disease and Kaposi’s sarcoma. J Interferon Cytokine Res 2002; 22: 1143–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Calcaterra F, Brambilla L, Colombo E, et al. Increased frequency and vasculogenic potential of endothelial colony–forming cells in patients with Kaposi’s sarcoma. J Invest Dermatol 2017; 137: 1533–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Boyman O, Conrad C, Dudii C, Kielhorn E, Nickoloff BJ, Nestle FO. Activation of dendritic antigen–presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis. Br J Dermatol 2005; 152: 1211–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Della Bella S, Nicola S, Brambilla L, et al. Quantitative and functional defects of dendritic cells in classic Kaposi’s sarcoma. Clin Immunol 2006; 119: 317–29.CrossRefPubMedGoogle Scholar
  28. 28.
    Cappelletti M, Presicce P, Calcaterra F, Mavilio D, Della Bella S. Bright expression of CD91 identifies highly activated human dendritic cells that can be expanded by defensins. Immunology 2015; 144: 661–7.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Tan Y, Wang Y, Li L, Xia J, Peng S, He Y. Chemokinelike factor 1–derived C–terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis. PLoS One 2015; 10:e0125073.Google Scholar
  30. 30.
    Samaniego F, Markham PD, Gendelman R, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi’s sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998; 152: 1433–43.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Seçkin D, Ozcan G, Demirăg A, Hizel N, Haberal M. The Koebner phenomenon in Kaposi’s sarcoma in a renal transplant recipient. Br J Dermatol 1998; 139: 346–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol 2008; 22: 324–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 2015; 41: 545–68.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma:a continuing conundrum. J Am Acad Dermatol 2008; 59: 179–206.CrossRefPubMedGoogle Scholar
  35. 35.
    Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years:is elderly–onset psoriasis a distinct subtype? Int J Dermatol 2012; 51: 53–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Brambilla L, Tourlaki A, Genovese G. Iatrogenic Kaposi’s sarcoma:a retrospective cohort study in an Italian tertiary care centre. Clin Oncol (R Coll Radiol) 2017; 29:e165–71.CrossRefGoogle Scholar
  37. 37.
    Wall D, McMenamin M, O’Mahony D, Irvine AD. Kaposi sarcoma in a patient with atopic dermatitis treated with ciclosporin. BMJ Case Rep 2013;2013.Google Scholar
  38. 38.
    Tartar D, Bhutani T, Huynh M, Berger T, Koo J. Update on the immunological mechanism of action behind phototherapy. J Drugs Dermatol 2014; 13: 564–8.PubMedGoogle Scholar
  39. 39.
    Wong T, Hsu L, Liao W. Phototherapy in psoriasis:a review of mechanisms of action. J Cutan Med Surg 2013; 17: 6–12.CrossRefPubMedGoogle Scholar
  40. 40.
    Nakamura S, Salahuddin SZ, Biberfeld P, et al. Kaposi’s sarcoma cells:long–term culture with growth factor from retrovirus–infected CD4+ T cells. Science 1988; 242: 426–30.CrossRefPubMedGoogle Scholar
  41. 41.
    Cohen CD, Horster S, Sander CA, Bogner JR. Kaposi’s sarcoma associated with tumour necrosis factor alpha neutralising therapy. Ann Rheum Dis 2003; 62: 684.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Bret J, Hernandez J, Aquilina C, Zabraniecki L, Fournie B. Kaposi’s disease in a patient on adalimumab for rheumatoid arthritis. Joint Bone Spine 2009; 76: 721–2.CrossRefPubMedGoogle Scholar
  43. 43.
    Martínez–Martínez ML, Pérez–García LJ, Escario–Travesedo E, Ribera–Vaquerizo PA. Kaposi sarcoma associated with infliximab treatment. Actas Dermosifiliogr 2010; 101: 462–4.CrossRefPubMedGoogle Scholar
  44. 44.
    Amadu V, Satta R, Montesu MA, Cottoni F. Kaposi’s sarcoma associated with treatment with adalimumab. Dermatol Ther 2012; 25: 619–20.CrossRefPubMedGoogle Scholar
  45. 45.
    Corbeil J, Rapaport E, Richman DD, Looney DJ. Antiproliferative effect of retinoid compounds on Kaposi’s sarcoma cells. J Clin Invest 1994; 93: 1981–6.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Caselli E, Galvan M, Santoni F, et al. Retinoic acid analogues inhibit human herpesvirus 8 replication. Antivir Ther 2008; 13: 199–209.PubMedGoogle Scholar
  47. 47.
    Morganroth GS. Topical 0.1% alitretinoin gel for classic Kaposi sarcoma. Arch Dermatol 2002; 138: 542–3.CrossRefPubMedGoogle Scholar
  48. 48.
    Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R, & International Panretin Gel KS Study Group. Phase III vehicle–controlled, multi–centered study of topical alitretinoin gel 0.1% in cutaneous AIDSrelated Kaposi’s sarcoma. Am J Clin Dermatol 2001; 2: 77–87.CrossRefPubMedGoogle Scholar
  49. 49.
    Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma:first European experience. Br J Dermatol 2006; 155: 856–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Robey RC, Bower M. Facing up to the ongoing challenge of Kaposi’s sarcoma. Curr Opin Infect Dis 2015; 28: 31–40.CrossRefPubMedGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Lucia Brambilla
    • 1
  • Giovanni Genovese
    • 1
  • Athanasia Tourlaki
    • 1
  • Silvia Della Bella
    • 2
    • 3
  1. 1.Department of Dermatology, Fondazione IRCCS Cà GrandaOspedale Maggiore PoliclinicoMilanItaly
  2. 2.University of MilanMilanItaly
  3. 3.Lab of Clinical and Experimental ImmunologyHumanitas Clinical and Research CenterRozzanoItaly

Personalised recommendations